We observed that DFS periods were significantly shorter (log-rank test; p = 9.44 x 10−13) for patients with tumours expressing high ARL6IP6 levels than those with low ARL6IP6 expression (Fig 8D). The gene discussed is ARL6IP6; the disease is neoplasm.